Unknown

Dataset Information

Protein degradation: expanding the toolbox to restrain cancer drug resistance.


ABSTRACT: Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several therapeutic strategies such as inhibition of proteasome with bortezomib and proteolysis-targeting chimeric have been developed. Compared with intervention at the transcriptional level, targeting the degradation process seems to be a more rapid and direct strategy. Proteasomal proteolysis and lysosomal proteolysis are the most critical quality control systems responsible for the degradation of proteins or organelles. Although proteasomal and lysosomal inhibitors (e.g., bortezomib and chloroquine) have achieved certain improvements in some clinical application scenarios, their routine

SUBMITTER: Ming H 

PROVIDER: S-EPMC9872387 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature